Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common ...
CRISPR Therapeutics (CRSP) posts new data from an early stage trial for CTX310, an in vivo gene editing therapy for heart ...
News-Medical.Net on MSN
One-time CRISPR therapy safely lowers cholesterol and triglycerides in early trial
In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...
In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...
Barchart on MSN
Should You Buy the Dip in Intellia Therapeutics Stock?
A patient’s death shook Intellia Therapeutics and sank its stock. Should investors buy the dip or steer clear?
BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced its first ...
Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct gene-editing experiments. The device, CRISPR-GPT, is an artificial intelligence lab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback